Introduction
============

Periodontal diseases are chronic, microbially influenced inflammatory disorders that have an effect on the structures that support teeth.[@b1-ccide-9-073] There are two major forms of periodontal diseases, gingivitis that is present almost ubiquitously in all populations and severe forms of periodontitis that affect 5%--15% of the global population.[@b2-ccide-9-073] In Nepal, 34% of subjects who are 35--44 years old have deep periodontal pockets.[@b3-ccide-9-073]

Emerging research and data show that the presence of periodontal inflammation can increase the risk of systemic diseases such as diabetes, principally through poor glycemic control. In the early 1990s, Loe[@b4-ccide-9-073] referred to periodontitis as the "sixth complication" of diabetes. Diabetes mellitus (DM) is a group of metabolic diseases that indicate high levels of glucose in the blood.[@b5-ccide-9-073] This condition constitutes a serious public health concern and is on the rise. The prevalence of diabetes has nearly doubled globally since 1980, rising from 4.7% to 8.5% in the adult population.[@b6-ccide-9-073] In the urban population in developing countries, the prevalence of DM is projected to double between 2000 and 2030.[@b7-ccide-9-073] In Nepal, studies have reported that, in the urban parts of the country, 15% of people ≥20 years and 20% of people \>40 years have diabetes.[@b8-ccide-9-073] The American Diabetes Association has acknowledged that periodontal disease is often found in people with diabetes.[@b9-ccide-9-073] Therefore, we can predict the increase in the burden of periodontal diseases as well.

There is abundant available literature that suggests that inadequately controlled diabetic patients exhibit a more severe breakdown of periodontal supporting tissues.[@b10-ccide-9-073],[@b11-ccide-9-073] The mechanism remains unclear but it has been proposed that there are vascular changes like gingival microangiopathy and elevation of serum proinflammatory cytokines that alter the response of periodontal tissues and delay postsurgical healing.[@b12-ccide-9-073] On the other hand, deteriorated periodontal health is associated with an increase in immuno-inflammatory response to bacterial lipopolysaccharides. There is release of mediators such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), prostaglandin E2 (PGE2), IL-8, IL-10, macrophage inflammatory protein (MIP1α) and MIP1β, and C-reactive protein (CRP)[@b13-ccide-9-073] that induces an elevated systemic chronic inflammatory state. These mediators are suggested to contribute to insulin resistance and thus to the cycle of hyperglycemia. Recently it has been reported that high-mobility group box 1(HMGB1) that functions as an inflammatory cytokine has an increased expression in patients with severe periodontitis.[@b14-ccide-9-073] In addition, the receptor for advanced glycation end products, which is frequently associated with proinflammatory responses, is a receptor for HMGB1 present in gingival tissues of patients with type 2 diabetes and chronic periodontitis.[@b14-ccide-9-073] This may explain why periodontitis worsens the glycemic control and also supports the notion that its treatment might improve the systemic disease state. However, intervention studies show a controversial effect of periodontal therapy on HbA1c levels.[@b15-ccide-9-073]--[@b18-ccide-9-073] No definite conclusion is reached as studies report different baseline glycemic conditions. Inflammation appears to be a common link between chronic periodontitis and type 2 diabetic patients. If the reduction in periodontal inflammation can improve insulin sensitivity, we can assume that it can act as an adjunct for better glycemic control, or at least delay the burden of diabetic complications. Therefore, the aim of this study was to see whether nonsurgical periodontal therapy improves the HbA1c level in Nepalese population.

Materials and methods
=====================

Study setting
-------------

This clinical study was carried out in the Department of Medicine (Diabetes and Endocrinology Unit) and the Periodontology and Oral Implantology Unit of National Academy of Medical Sciences (NAMS), Kathmandu. The study was reviewed and approved by the Institutional Review Board, Ethical Committee of NAMS, Bir Hospital, Kathmandu, Nepal, in accordance with the ethical principles of the World Medical Association Declaration of Helsinki.

Sample size estimation
----------------------

The ideal sample size to ensure adequate power for this clinical study was calculated considering an SD of 0.8 for the test group and 2.08 for the control group with a true difference of 1. Based on the abovementioned values, it was found that 41 patients per group were necessary to provide 80% power at 95% CI (α=0.05). Sample size was carried out by RV Lenth using the Java Applets for Power and Sample Size 2006, version 1.75 (University of Iowa, Iowa City, IA, USA).

Criteria for selection
----------------------

Inclusion criteria for both the groups in the study were as follows: 1) age 35--70 years; 2) type 2 DM with HbA1c values of 6%--8%; 3) body mass index (BMI) of 19--26 kg/m^2^ in women and 20--27 kg/m^2^ in men; 4) medically stable ambulatory patients; 5) diagnosis of moderate to severe generalized chronic periodontitis for both the groups, with at least one tooth having a true probing depth (PD) of ≥5--7 mm in each quadrant (either anterior or posterior); and 6) presence of \>16 teeth in the mouth, excluding third molars. Exclusion criteria for both the groups were as follows: 1) presence of systemic diseases (other than DM and hypertension with no change in their medications; participants taking calcium channel blockers were excluded); 2) smoking or alcoholism; 3) diabetic complications; 4) intake of systemic antibiotics in the last 3 months; 5) periodontal treatment 3 months prior to the study; 6) pregnant adults; and 7) failure to give an informed consent.

Study patients
--------------

An open-label comparative clinical trial was performed. The duration of the study period was from July 2012 to January 2013. A convenient sampling technique was used (ie, inclusion of those who met the inclusion criteria). The patients were assigned into two groups and in an alternative sequence, they were placed in the test (treatment) group and the control (nontreatment) group and were analyzed for clinical and metabolic parameters ([Figure 1](#f1-ccide-9-073){ref-type="fig"}).

Clinical data collection
------------------------

### Periodontal treatment

Written informed consent was acquired from each patient. The clinical examination was performed by a single examiner under artificial light with help of a mouth mirror and a periodontal probe (University of North Carolina-15, Hu-Friedy, Chicago, IL, USA). Eligibility was verified and it was ensured that all necessary pretreatment preparations had been carried out. Patients of both the groups (test and control) received oral hygiene instructions at baseline. They were instructed to brush their teeth using the modified bass toothbrushing technique and interproximal brushes where needed. The test group received nonsurgical periodontal therapy in the form of full-mouth scaling and root surface debridement (RSD). An ultrasonic device (Cavitron; Dentsply, York, PA, USA) was utilized to remove supragingival calculus in the first session. Subgingival scaling and RSD were performed with the help of a hand instrument (Gracey curets; Hu-Friedy) using only light pressure with complete overlapping of instrumentation strokes of limited duration to obtain smooth surfaces[@b19-ccide-9-073] in two appointments. The control group received no periodontal treatment during the 3-month study period. Both the groups were instructed to continue with their medical treatment, diet, and lifestyle without modifications during the study period. The clinical parameters such as gingival index (GI), PD, and clinical attachment level (CAL) were recorded for six sites of each tooth, excluding third molars. Teeth that had the deepest site were included for analysis of PD and CAL from four different quadrants of each patient. Altogether 656 sites were analyzed. Gingival status was measured for each tooth according to the criteria for GI.[@b47-ccide-9-073] PD was measured as the distance between gingival margin and bottom of sulcus/pocket and CAL as the distance between cementoenamel junction and bottom of sulcus/pocket.

Approximately 3 months after the last periodontal treatment session, evaluation of clinical periodontal parameters was carried out in both the test and control groups. Deep sites were reevaluated and the decision was made for further subgingival debridement or surgical intervention based on bleeding on probing and remaining PD, in the test group. The control group at 3 months received the periodontal therapy according to its measured periodontal status.

### Evaluation of metabolic status

The blood sample of each study patient was sent to a certified clinical laboratory and analyzed for HbA1c level (HumaMeter A1c test, which expresses results in both International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) (mmol/mol) and National Glycohemoglobin Standardization Program (NGSP)/Diabetes Control and Complications Trial (DCCT) (%) values; National Public Health Laboratory, under Department of Health Services and Ministry of Health & Population, Kathmandu, Nepal.). There has been substantial interest in using HbA1c as a diagnostic test for diabetes as it indicates an average blood glucose level of the past 2--3 months. It is also a screening test for individuals at an increased risk for the disease.[@b20-ccide-9-073] The reasonable level of HbA1c is 4%--6%, and \<7% is considered as good diabetes control, 7%--8% as moderate control, and \>8% as poor metabolic control.[@b21-ccide-9-073] The HbA1c levels were measured at baseline and at 3 months for both the groups.

Statistical analysis
--------------------

The collected data were entered in MS Excel 2007 and converted in a statistical software package (SPSS for Windows version 11.0; SPSS Inc., Chicago, IL, USA). The available data, only for patients who had completed the study, were analyzed using statistical descriptive indices of central tendency and dispersion (means and SDs). For inferential statistics, chi-square test was used. Paired *t*-test and independent *t*-test were applied to find out the significant difference between the groups and within the group. The level of significance was considered *p*\<0.05 where CI 95%.

Results
=======

There were 82 type 2 diabetic patients with moderate to severe periodontitis in the study sample. The demographic characteristics of both the groups are shown in [Table 1](#t1-ccide-9-073){ref-type="table"}. As regards the associated disease in this study, systemic hypertension was present in 17 (41.46%) patients in the test group and 20 (48.78%) in the control group (p=0.505).

Groups at baseline
------------------

There was no significant difference between GI (*p*=0.163) and CAL (*p*=0.180) between the groups at baseline. There was a slight increase in PD (*p*=0.007) of the test group compared to that of the control group. The HbA1c levels of both the groups were similar (*p*=0.437) ([Table 1](#t1-ccide-9-073){ref-type="table"}).

Comparison of periodontal parameters at 3 months
------------------------------------------------

In the test group, GI scores dropped from 1.6±0.34 to 1.3±0.33, which was statistically significant (*p*\<0.001), whereas in the control group, an insignificant increase was observed from 1.45±0.33 to 1.48±0.31 (*p*=0.100) ([Table 1](#t1-ccide-9-073){ref-type="table"}; [Figure 2](#f2-ccide-9-073){ref-type="fig"}). Similarly, in the test group, PD and CAL decreased from 5.88±0.86 to 4.97±0.90 mm (*p*\<0.001) ([Figure 3](#f3-ccide-9-073){ref-type="fig"}) and from 5.51±0.99 to 5.21±1.12 mm (*p*\<0.001) ([Figure 4](#f4-ccide-9-073){ref-type="fig"}), respectively, which was statistically significant. In the control group, a statistically insignificant increase was observed for PD and CAL from 5.63±0.84 to 5.68±0.90 mm (*p*=0.258) and from 5.66±1.06 to 5.71±1.07 mm (*p*=0.103), respectively. Significant changes were observed in GI, PD, and CAL (*p*\<0.01, *p*\<0.001, and *p*\<0.001, respectively) ([Table 1](#t1-ccide-9-073){ref-type="table"}; [Figures 2](#f2-ccide-9-073){ref-type="fig"}[](#f3-ccide-9-073){ref-type="fig"}--[4](#f4-ccide-9-073){ref-type="fig"}) in the test group compared to the control group.

Comparison of metabolic parameters at 3 months
----------------------------------------------

In the test group, there was a reduction of 1.8% (1.83±6.95) in the HbA1c level. The values decreased from 6.71±0.50% to 6.58±0.54%, but the values were statistically insignificant (*p*=0.078). The control group showed a minor increase of 0.43% (--0.43±3.71) (*p*=0.535) ([Figure 5](#f5-ccide-9-073){ref-type="fig"}). However, a significant improvement in the HbA1c levels (0.07%) was observed in the test group when compared to the control group (*p*=0.029) ([Table 1](#t1-ccide-9-073){ref-type="table"}; [Figure 5](#f5-ccide-9-073){ref-type="fig"}).

Discussion
==========

This study focused on the short-term effect of scaling and RSD on the HbA1c level. The results of this study were statistically significant enough to prove the efficiency of nonsurgical periodontal therapy in improving glycemic control by 0.07% at the end of 3 months. The reported results also showed a significant improvement in clinical periodontal parameters in the test group, with the PD reduction by 0.9 mm and gain in CAL by 0.3 mm, whereas in the control group there was a slight increase in PD, and CAL by 0.05 mm.

HbA1c is one of the most important markers in type 2 diabetic patients and is used to evaluate the severity as well as the glucose control condition.[@b20-ccide-9-073] A study done by Demmer et al[@b22-ccide-9-073] reported that in nondiabetic patients, periodontitis anticipates the progression of HbA1c level and its reduction is likely to lower the potential of having the disease. The HbA1c levels indicate the binding between the glucose and hemoglobin molecule and changes in HbA1c level can be detected during half of the life span of erythrocyte cells (30--90 days). Therefore the HbA1c levels were evaluated, and reexamination was done 3 months after scaling and RSD.

Several systematic reviews have favored the beneficial effect of periodontal therapy on HbA1c level.[@b23-ccide-9-073]--[@b25-ccide-9-073] Poorly controlled diabetic patients show a fast decrease in HbA1c level after scaling and RSD compared to well-controlled diabetic patients.[@b26-ccide-9-073]--[@b28-ccide-9-073] A rebound effect of the HbA1c level to baseline is also seen. These individuals are prone to infections and their health condition is associated with complications that would require a change in medications or diet. Therefore, moderately to well-controlled patients were evaluated in this study. A significant decrease in the HbA1c level with 3 months of periodontal treatment was seen in the test group when compared to the control group. The improvement seen may be due to the impact of local oral infection and periodontal inflammation that was reduced after the therapy in the test group. This was further maintained by oral hypoglycemic medications taken by the patients. Our study is in agreement with the study done by Kiran et al[@b29-ccide-9-073] in 44 patients that showed a marked improvement in periodontal parameters and enhancement in metabolic status, possibly due to the reduction in gingival inflammation. Similarly, studies done by Dag et al[@b30-ccide-9-073] and Navarro-Sanchez et al[@b31-ccide-9-073] found a significant improvement in glycemic control from 3 months and later at 6 months in moderately controlled type 2 diabetic patients. The decrease was attributed to a reduction in systemic and local inflammation via the decrease in the inflammatory mediators like TNF-α, IL-1β, PGE2, IL-8, IL-10, and CRP. A meta-analysis[@b32-ccide-9-073] has supported the hypothesis of the decrease in inflammatory burden of TNF-α and CRP which thus results in an improved insulin sensitivity[@b33-ccide-9-073] after periodontal therapy. This favors the explanation of the link between these two chronic diseases. Recently, studies have reported that nonsurgical periodontal treatment was sufficient to reverse even a prediabetes condition to a healthy state in a large proportion of the participants.[@b34-ccide-9-073],[@b35-ccide-9-073]

The mean reduction in HbA1c level seen in our study is 0.07%. However, it should be noted that the 2015 Cochrane Collaboration systematic review reported a mean percentage reduction of 0.29% in HbA1c at 3--4 months.[@b36-ccide-9-073] A recent long-term study in a clinical setting showed an improved glycemic control by a mean reduction of --0.074% in HbA1c.[@b37-ccide-9-073] The percentage of reduction is small in our study, but it may help in improving patients' overall oral health and quality of life, which may in turn help improve their systemic condition.

Conversely, there were some studies that did not show any improvement in moderately controlled diabetic patients. The low levels of HbA1c were considered the reason for the absence of correlation between periodontal improvement and glycemic control.[@b38-ccide-9-073],[@b39-ccide-9-073] In addition, a limited impact of periodontal therapy on serum inflammatory mediators was observed as well.[@b40-ccide-9-073] Whether nonsurgical periodontal therapy can improve metabolic status is still controversial. Recently, the findings of the Diabetes and Periodontal Therapy Trial done by Engebretson et al[@b41-ccide-9-073] did not support the use of nonsurgical periodontal treatment to lower HbA1c levels. However, this study was criticized in further subsequent studies[@b42-ccide-9-073],[@b43-ccide-9-073] as participants had higher BMI levels, and baseline HbA1c levels closer to reflecting good glycemic control. Nevertheless, individuals in our study had BMI values slightly less than overweight. It has been shown that nonobese individuals tend to show more decrease in HbA1c levels than obese individuals, as pronounced obesity masks the decrease in inflammatory response by periodontal therapy.[@b34-ccide-9-073],[@b44-ccide-9-073] The differences in study design may explain the variations in results in moderately controlled diabetic patients. Furthermore, periodontitis varies among different population groups that relate to specific host lineage, and therefore their association as well as response to treatment may differ worldwide in diabetic patients.

The extent and severity of periodontitis in patients with diabetes are other questionable issues. Studies[@b30-ccide-9-073],[@b31-ccide-9-073],[@b45-ccide-9-073] showing a significant improvement in levels of HbA1c have moderate to severe attachment loss with deep pockets. It might be assumed that, to have an effect on metabolic levels, a reduction of deep periodontal pockets is necessary. Therefore, patients with true deep pockets were included in the present study that showed a significant improvement in PDs and CALs. The findings of this study are similar to the studies showing improvement in periodontal parameters in diabetic patients.[@b29-ccide-9-073],[@b31-ccide-9-073],[@b46-ccide-9-073] This further confirms the favorable response of type 2 diabetic patients to periodontal therapy. Though the study was only carried out for 3 months, we can assume the presence of deep remaining pockets at certain sites and further improvement may be observed over 6 or 12 months. This emphasizes that a definitive supportive periodontal therapy is required to maintain the glycated level, as other factors of uncontrollable diabetes and the inappropriate dose of hypoglycemic medications were stable.

Recommendations to clinicians and general practitioners are still warranted for the holistic approach to global oral health. A limitation of the present study design is that it is a small case--control study with short duration. Additionally, the study was not blinded, and individuals with high BMI and increased HbA1c levels were not included.

Conclusion
==========

Scaling and RSD resulted in lowering the HbA1c level as well as improvement in periodontal disease status. However, large-scale studies with similar designs are required to provide evidence of the effect of periodontal therapy in type 2 diabetic patients.
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![Flowchart of the study.\
**Abbreviations:** OHI, oral hygiene instructions; RSD, root surface debridement.](ccide-9-073Fig1){#f1-ccide-9-073}

![Comparison of GI (mean ± SD) between test and control group at baseline and at 3 months. Three months after nonsurgical periodontal therapy, the test group showed a significant reduction in GI (^\*^*p*\<0.001).\
**Abbreviation:** GI, gingival index.](ccide-9-073Fig2){#f2-ccide-9-073}

![Comparison of PD (mean ± SD) between test and control group at baseline and at 3 months. Three months after nonsurgical periodontal therapy, the test group showed a significant reduction in PD (^\*^*p*\<0.001).\
**Abbreviation:** PD, probing depth.](ccide-9-073Fig3){#f3-ccide-9-073}

![Comparison of CAL (mean ± SD) between test and control group at baseline and at 3 months. Three months after nonsurgical periodontal therapy, the test group showed a significant reduction in CAL (^\*^*p*\<0.001).\
**Abbreviation:** CAL, clinical attachment level.](ccide-9-073Fig4){#f4-ccide-9-073}

![Comparison of HbA1c levels (mean ± SD) between test and control group at baseline and at 3 months. In the test group, there was a reduction in HbA1c level from baseline to 3 months, but it was not statistically significant (*p*=0.078). There was a significant reduction between the test and control group at 3 months (^\*^*p*\<0.05).](ccide-9-073Fig5){#f5-ccide-9-073}

###### 

Demographic characteristics with clinical and metabolic parameters (mean ± SD) at baseline and 3 months

  Variable                                                   Test         Control       *p*-value[\*](#tfn1-ccide-9-073){ref-type="table-fn"}
  ---------------------------------------------------------- ------------ ------------- -------------------------------------------------------
  Males                                                      27           29            
  Females                                                    14           12            
  Age (years)                                                50.66±7.70   53.80±9.16    0.096
  Duration of DM (years)                                     6.32±4.21    6.24±4.00     0.936
  BMI (kg/m^2^)                                              24.78±1.85   24.65±1.79    0.74
  GI                                                                                    
   Baseline                                                  1.55±0.34    1.45±0.33     0.163
   3 months                                                  1.28±0.33    1.48±0.31     0.006
   Difference                                                0.3          0.03          \<0.001
   *p*-value[\*\*](#tfn2-ccide-9-073){ref-type="table-fn"}   0.001        0.100         
  PD (mm)                                                                               
   Baseline                                                  5.88±0.86    5.63±0.84     0.007
   3 months                                                  4.97±0.90    5.68±0.90     0.001
   Difference                                                0.91         0.05          
   *p*-value[\*\*](#tfn2-ccide-9-073){ref-type="table-fn"}   0.001        0.258         \<0.001
  CAL (mm)                                                                              
   Baseline                                                  5.51±0.99    5.66±1.06     0.180
   3 months                                                  5.21±1.12    5.71±1.07     0.001
   Difference                                                0.3          0.05          
   *p*-value[\*\*](#tfn2-ccide-9-073){ref-type="table-fn"}   0.001        0.103         \<0.001
  HbA1c levels (%)                                                                      
   Baseline                                                  6.71±0.50    6.80±0.45     0.437
   3 months                                                  6.58±0.54    6.82±0.43     0.029
  Percentage reduction                                       1.83±6.95    --0.43±3.71   0.070
   *p*-value[\*\*](#tfn2-ccide-9-073){ref-type="table-fn"}   0.078        0.535         --

**Notes:**

Comparison between the test and control group at baseline and third month.

Comparison of baseline and third month within the group.

**Abbreviations:** BMI, body mass index; CAL, clinical attachment level; DM, diabetes mellitus; GI, gingival index; PD, probing depth.
